Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06852625
PHASE1

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients

Sponsor: Fundacion Clinic per a la Recerca Biomédica

View on ClinicalTrials.gov

Summary

The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant recipients.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-05

Completion Date

2028-03

Last Updated

2025-02-28

Healthy Volunteers

No

Interventions

BIOLOGICAL

Autologous Tolerogenic Dendritic Cells

• Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a period of 30 minutes (up to 1 hour) will administer between Day 1 and Day 3 after transplantation.

Locations (7)

Hospital Germans Trias i Pujol

Badalona, Barcelona, Spain

Hospital del Mar

Barcelona, Barcelona, Spain

Fundació Puigvert

Barcelona, Barcelona, Spain

Hospital Vall d'Hebron

Barcelona, Barcelona, Spain

Hospital Clinic Barcelona

Barcelona, Barcelona, Spain

Hospital Universitari Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Universitario Miguel Servet

Zaragoza, Zaragoza, Spain